Core Viewpoint - I-Mab is hosting a virtual investor event on July 8, 2025, to discuss new data on givastomig, a bispecific antibody targeting Claudin 18.2, following its presentation at ESMO GI 2025 [2][4] Group 1: Event Details - The event will feature Dr. Samuel J. Klempner, who will present new data on givastomig in combination with immunochemotherapy for Claudin 18.2-positive metastatic gastric cancers [3][4] - The data will be presented live at the ESMO GI 2025 on July 2, 2025, with a Mini Oral presentation scheduled for 16:50 CEST (10:50am EDT) [3] - A live Q&A session will follow the formal presentation, and a replay will be available on I-Mab's website for 90 days [4] Group 2: Givastomig Overview - Givastomig (TJ033721 / ABL111) is a bispecific antibody designed to target Claudin 18.2-positive tumor cells, activating T cells through the 4-1BB signaling pathway [6][9] - It is being developed for first-line treatment of metastatic gastric cancers, with potential applications in other solid tumors [6][9] - Phase 1 trials have shown promising anti-tumor activity while minimizing common toxicities associated with other 4-1BB agents [6][9] Group 3: Clinical Study Insights - An ongoing Phase 1b study is evaluating givastomig in combination with nivolumab and chemotherapy for first-line treatment of Claudin 18.2-positive metastatic gastric cancers [7] - The dose escalation phase is complete, and enrollment in the first dose expansion cohort (n=20) has finished ahead of schedule, with continued progress in the second cohort [7] - The study builds on positive Phase 1 monotherapy data, indicating strong potential for further development [7] Group 4: Company Background - I-Mab is a U.S.-based global biotech company focused on precision immuno-oncology agents for cancer treatment, with givastomig as a key product in its pipeline [9] - The company is jointly developing givastomig with ABL Bio, sharing worldwide rights except for Greater China and South Korea [8]

Summary of I-Mab (IMAB) Conference Call - June 17, 2025 Company Overview - **Company**: I-Mab (IMAB) - **Focus**: Development of innovative therapies for cancer, particularly targeting Claudin 18.2 in gastric cancer - **Current Status**: Transitioned to a capital-efficient model with a focus on the US market, following a divestiture of operations in China [6][12] Clinical Pipeline - **Key Asset**: Giva (Claudin 18.2 bispecific antibody) - **Clinical Stage**: Three clinical stage assets, with Giva being the primary focus [7][8] - **Upcoming Presentation**: Mini oral presentation scheduled for ESMO GI on July 2, 2025 [2][85] Core Points and Arguments - **Giva's Mechanism**: Giva is designed to enhance the standard of care for frontline gastric cancer without altering existing treatments [8][10] - **Efficacy Data**: - Monotherapy showed an Objective Response Rate (ORR) of 18% in heavily treated populations [9] - Combination studies with standard care (nivo chemo) demonstrated promising ORR and safety profiles [10][11] - **Market Opportunity**: - Addressable market for frontline Claudin 18.2 positive patients estimated at $12 billion in the US, EU, and Japan [11] - Gastric cancer is a significant unmet medical need with a low five-year survival rate of 7% for metastatic cases [10][11] Safety and Tolerability - **Safety Profile**: Giva demonstrated a favorable safety profile with minimal toxicity compared to other treatments [24][36] - **Comparison with Competitors**: Giva's grade 3 and above treatment-related adverse events were reported at 33%, significantly lower than competitors [41][42] Differentiation from Competitors - **Broad Eligibility**: Giva targets a wider range of Claudin 18.2 positive patients with a cutoff of 1% expression, unlike competitors with higher thresholds [31][39] - **Combination Potential**: Giva can be added to existing regimens without modifying standard care, making it suitable for frontline therapy [35][36] Future Development Strategy - **Focus on Gastric Cancer**: Commitment to developing Giva in frontline metastatic gastric cancer, with potential exploration in locally advanced settings and other GI cancers [55][75] - **Exploration of Other Tumor Types**: Interest in testing Giva in pancreatic and biliary tract cancers due to high Claudin 18.2 expression [55][75] Key Takeaways for Investors - **Upcoming Data**: Investors should look for data from the ESMO GI presentation, particularly regarding safety, efficacy, and the potential for Giva to improve patient outcomes [64][66] - **Long-term Potential**: Giva's unique properties and promising early data position it well for future success in treating gastric cancer and potentially other malignancies [84][85] Conclusion - I-Mab is poised for significant developments with Giva, focusing on addressing unmet needs in gastric cancer while maintaining a strong safety profile and broad eligibility for patients. The upcoming ESMO GI presentation is anticipated to provide critical data that could influence future investment and development strategies [82][84]

Market Capitalization Overview - New Oriental has a market capitalization of 14.264 billion [2] - TAL Education (好未来) has a market capitalization of 8.983 billion [2] - Vipshop (唯品会) has a market capitalization of 7.770 billion [2] - Zai Ding Pharmaceutical (再鼎医药) has a market capitalization of 4.357 billion [2] - RELX has a market capitalization of 3.519 billion [2] Stock Performance - New Oriental's stock increased by 0.39 (+2.21%) [2] - TAL Education's stock increased by 1.00 (+5.02%) [2] - Vipshop's stock increased by 1.47 (+3.15%) [2] - Zai Ding Pharmaceutical's stock increased by 0.40 (+0.96%) [2] - RELX's stock increased by 0.37 (+2.98%) [2] Additional Companies - Huya (虎牙) has a market capitalization of 1.059 billion with a stock increase of 0.04 (+1.03%) [2] - iQIYI (爱奇艺) has a market capitalization of 2.479 billion with a stock increase of 0.14 (+1.52%) [2] - Lexin (乐信) has a market capitalization of 1.529 billion with a stock increase of 0.34 (+4.15%) [2] - Yihua Smart (宜人智科) has a market capitalization of 0.548 billion [2] Smaller Market Players - Sohu has a market capitalization of 0.323 billion with a stock decrease of 0.04 (-2.02%) [3] - Xiaoniu Electric (小牛电动) has a market capitalization of 0.257 billion [3] - Baozun (宝尊电商) has a market capitalization of 0.173 billion [3] - Huami Technology (华米科技) has a market capitalization of 0.164 billion [3]

Core Viewpoint - I-Mab has regained compliance with Nasdaq's minimum bid price requirement, allowing its American Depositary Shares to continue trading on the exchange [1][2]. Company Overview - I-Mab is a U.S.-based global biotech company focused on developing precision immuno-oncology agents for cancer treatment [3]. - The company's leading pipeline product is givastomig, a bispecific antibody targeting Claudin 18.2, designed for treating Claudin 18.2-positive gastric cancers [3]. - Givastomig is being developed for first-line metastatic gastric cancers and shows potential in other solid tumors, demonstrating strong tumor-binding properties and anti-tumor activity in Phase 1 trials [3].

I-Mab Sponsored ADR (IMAB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, IMAB's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross."There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving average. ...

Market Capitalization Overview - New Oriental has a market capitalization of 14.065 billion [2] - TAL Education (好未来) has a market capitalization of 8.413 billion [2] - Miniso (名创优品) has a market capitalization of 5.728 billion [2] - JD.com (京东) has a market capitalization of 66.01 billion [2] - iQIYI (爱奇艺) has a market capitalization of 2.439 billion [3] Stock Performance - New Oriental's stock decreased by 0.15 (-0.77%) [2] - TAL Education's stock decreased by 0.21 (-1.20%) [2] - Miniso's stock increased by 1.24 (+2.61%) [2] - iQIYI's stock decreased by 0.05 (-0.48%) [3] - JD.com's stock increased by 0.39 (+3.92%) [3] Company Comparisons - New Oriental's market cap is significantly higher than that of TAL Education, which is about 60% of New Oriental's value [2] - Miniso's market cap is approximately 67% of TAL Education's market cap [2] - iQIYI's market cap is lower than that of Miniso, indicating a weaker market position [3] Industry Insights - The overall market performance shows a mixed trend with some companies experiencing gains while others face declines [2][3] - The education sector, represented by New Oriental and TAL Education, shows volatility with both companies experiencing stock price fluctuations [2] - E-commerce and entertainment sectors, represented by Miniso and iQIYI, also reflect varying market sentiments [2][3]

Market Capitalization Summary - New Oriental has a market capitalization of 13.696 billion [2] - TAL Education has a market capitalization of 8.011 billion [2] - Vipshop has a market capitalization of 8.175 billion [2] - 51Talk has a market capitalization of 7.533 billion [2] - Xunlei has a market capitalization of 6.438 billion [2] - 76.67 billion market capitalization for another unspecified company [2] - 56.88 billion market capitalization for another unspecified company [2] - 32.89 billion market capitalization for another unspecified company [2] - 16.27 billion market capitalization for another unspecified company [2] - 12.30 billion market capitalization for Lexin [2] - 9.91 billion market capitalization for Youdao [2] - 5.19 billion market capitalization for Dada [2] Stock Performance - New Oriental's stock increased by 0.09 (+0.50%) [2] - TAL Education's stock decreased by 0.01 (-0.28%) [2] - Vipshop's stock increased by 0.27 (+1.46%) [2] - 51Talk's stock decreased by 1.09 (-2.28%) [2] - Xunlei's stock increased by 0.16 (+1.11%) [2] - 76.67 billion market capitalization company increased by 0.13 (+1.24%) [2] - 56.88 billion market capitalization company decreased by 0.14 (-0.77%) [2] - 32.89 billion market capitalization company increased by 0.65 (+2.58%) [2] - 16.27 billion market capitalization company increased by 0.02 (+1.20%) [2] - Lexin's stock increased by 0.22 (+2.68%) [2] - Youdao's stock decreased by 0.11 (-1.21%) [2] - Dada's stock decreased by 0.06 (-1.58%) [2] Additional Company Insights - The market capitalization of various companies ranges significantly, with some exceeding 10 billion [2] - Companies like New Oriental and TAL Education show contrasting stock performance trends, indicating varying investor sentiment [2] - The overall market appears to be volatile, with both increases and decreases in stock prices across different companies [2]

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

I-Mab (IMAB) 2025 Conference June 05, 2025 03:45 PM ET Speaker0 Great. I think we can get started. Good afternoon, everyone. Thank you for attending Jefferies Healthcare Conference. My name is Yifan Shi from Jefferies Biotech Research Team. Today, we are very pleased to have Doctor. Sheng Fu, CEO of IMAP, and Doctor. Philip Dennis, CMO of IMAP, in for this session. Welcome. Speaker1 Thank you. Speaker0 So, to get start, so for those who may be less familiar with your story, could you please provide a high l ...

Format: Fireside Chat Moderator: Andres Maldonado, PhD, Senior Analyst, H.C. Wainwright I-Mab Speakers: Date: Tuesday, June 17, 2025 Time: 10:00 AM to 11:00 AM ET Webcast Link: Register here The webcast of the event will be accessible from News & Events page of the I-Mab website for 90 days. About I-Mab ROCKVILLE, Md., June 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment ...